ECIL Guidelines for the Diagnosis of Pneumocystis Jirovecii Pneumonia in Patients With Haematological Malignancies and Stem Cell Transplant Recipients

This is a clinical practice guideline for the diagnosis of Pneumocystis jirovecii pneumonia (PCP) in patients following treatment for hematological malignancies or after hematopoietic stem cell transplantation (HSCT). This guideline highlights the main differences in clinical presentation of PCP between hematology patients and other immunocompromised populations, especially HIV-infected patients, and the main risks factors including pre-existing respiratory disease, and genetic predisposition. The risk factors associated with specific therapies, such as corticosteroids, chemotherapeutic agents, and monoclonal antibodies are also addressed.